Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 3, 2018. The primary purpose of the filing is to announce a definitive agreement to acquire TESARO Inc., an oncology-focused biopharmaceutical company based in Waltham, Massachusetts. The transaction is designed to strengthen GSK's pharmaceutical business by accelerating its oncology pipeline and commercial capabilities.
Key Financial Metrics
- Transaction Value: Aggregate cash consideration of approximately $5.1 billion (£4.0 billion), including the assumption of TESARO's net debt.
- Offer Price: $75 per share in cash, representing a 110% premium to TESARO's 30-day Volume Weighted Average Price of $35.67.
- TESARO Revenue: Zejula (niraparib) generated $166 million in revenue for the nine months ended September 30, 2018.
- TESARO Net Loss: $466 million for the nine months ended September 30, 2018.
- TESARO Gross Assets: $711 million as of September 30, 2018.
- GSK Dividend: GSK expects to pay 80p in dividends for 2018, with no change to its current dividend policy.
- Funding: The acquisition will be funded from cash resources and a new acquisition facility.
Material Changes and Strategic Impact
The acquisition represents a significant strategic shift for GSK, focusing on expanding its oncology portfolio. Key assets acquired include Zejula (niraparib), a PARP inhibitor approved for ovarian cancer, and a pipeline of immunotherapy candidates targeting PD-1, TIM-3, and LAG-3. The filing notes that GSK expects the acquisition and associated investments to impact Adjusted Earnings Per Share (EPS) for the first two years by mid to high single-digit percentages. The acquisition is expected to become accretive to Adjusted EPS by 2022.
Guidance, Outlook, and Risks
- 2018 Guidance: GSK's guidance for full-year 2018 Adjusted EPS growth remains unchanged at 8% to 10% at Constant Exchange Rates (CER).
- Long-term Outlook: While GSK continues to expect to deliver on its Group Outlooks to 2020, the company now expects Adjusted EPS growth at CER for the 2016-2020 period to be at the bottom end of the mid to high single-digit percentage Compound Annual Growth Rate (CAGR) range.
- Transaction Timeline: The transaction is expected to complete in the first quarter of 2019, subject to customary closing conditions, including regulatory approvals (e.g., US Federal Trade Commission) and the tender of at least 50% plus one share of TESARO stock.
- Risks: Risks include the possibility that closing conditions may not be satisfied, regulatory delays or prohibitions, integration challenges, and the diversion of management attention. Forward-looking statements regarding clinical trial results (e.g., PRIMA study results expected in H2 2019) and commercial success are subject to uncertainty.
Investor Verification Checklist
- Verify the final closing date and confirmation of regulatory approvals (FTC and others) in Q1 2019.
- Monitor the tender offer results to ensure the 50% plus one share threshold is met.
- Review upcoming clinical trial data for Zejula, specifically the PRIMA study results expected in the second half of 2019.
- Track GSK's quarterly Adjusted EPS performance to assess the impact of the acquisition costs and integration expenses against the "mid to high single digit" reduction forecast.
- Confirm the execution of the new acquisition facility and the impact on GSK's overall debt profile and liquidity.